Rationale: Post-traumatic stress disorder (PTSD) is a debilitating psychiatric condition that can develop after experiencing a traumatic event. Although effective treatment is available, including exposure therapy or cognitive behavioural therapy, about 30% of patients with PTSD do not respond to these treatments. Therefore, currently available treatments need to be improved. Intranasal administration of the neuropeptide oxytocin is a promising candidate for medication-enhanced psychotherapy (MEP), as oxytocin has been shown to increase sensitivity for social reward.